Field report SE-50 / M3
Filed from the territory
FDA Panel Backs Galleri Blood Test for 50-Plus Cancers
An FDA advisory panel recommended approval of GRAIL's Galleri test for 50-plus cancers on Sept. 23, 2026, despite data showing it missed 69% of cases and failed to cut late-stage diagnoses.
- Grid
- SE-50 / M3
- Surveyed
- November 17, 2026
- Reading
- 4 min read
- Correspondent
- Elena Vasquez

Field notes
- FDA advisory panel voted Sept. 23, 2026 to recommend approval of the Galleri multi-cancer blood test
- The test missed 69% of cancers across all stages and 80% of early-stage cancers over three screening rounds
- The trial failed its primary goal of reducing late-stage cancer incidence; no evidence it lowers mortality
- False positive rate is 0.5% — one in 200 tested — with a 52% positive predictive value
- Out-of-pocket cost is US$949 per test
An FDA advisory panel voted on Sept. 23, 2026 to recommend approval of the Galleri blood test, a single-draw screen for more than 50 cancers — even though clinical trial data shows it missed 69% of cancer cases across all stages and failed to reduce diagnoses of late-stage disease, the trial's primary goal.
The panel's votes were split and, in two cases, counterintuitive. Advisors voted 10-0 that the test is safe, 6-4 that it is effective, and 7-2 with one abstention that benefits outweigh risks. Several panelists conditioned their "yes" on effectiveness by demanding that GRAIL, the test's maker, drop the word "early" from the "multi-cancer early detection" label. The FDA has not announced when it will make a final decision. Requests for comment from GRAIL went unanswered.
Cancer is not the leading cause of death in the United States — heart disease ranks first — but it accounts for more years of potential life lost and is increasingly striking people at younger ages, according to public-health data cited by Andrew Wolf, professor emeritus of medicine at the University of Virginia and chair of the American Cancer Society's screening guideline development group, who analyzed the evidence.
What does the Galleri test actually do?
Galleri is a screening test, not a diagnostic one. A positive result requires further evaluation to determine whether cancer is present and of what type. The test looks for DNA fragments in blood carrying methylation markers — unique tags on cancer DNA — and uses machine learning algorithms to generate a positive or negative result. It also predicts where in the body a detected cancer originated.
It screens for DNA signals from more than 50 cancers, including the 12 that account for almost two-thirds of U.S. cancer deaths, such as lung and pancreatic cancer. Currently recommended screenings cover only four cancer types.
Where the test performs well
The false positive rate is about 0.5% — one person out of every 200 tested — compared with roughly 10% for many recommended tests, such as the Cologuard stool test for colorectal cancer. That translates into a positive predictive value of 52% across three annual screens, meaning more than half of positive results led to a cancer diagnosis. Most recommended screening tests, including mammography, stool tests and HPV testing, have PPVs below 10%.
The test also pinpoints a cancer's origin with striking accuracy. In one study of 32,000 U.S. adults age 50 and older, cancer was diagnosed in about 0.5% — 173 patients — and Galleri correctly predicted the cancer type in 91% of them, according to published trial data. That specificity can steer clinicians toward targeted evaluations rather than whole-body searches.
Where it falls short
The test detected less than 31% of cancers at all stages over three annual screening rounds, missing 69% of cases. For early-stage cancers — the point of any screening test — detection was only 21% over three years, meaning almost 80% were missed.
The trial's main goal was to show the test could reduce the incidence of late-stage cancers over three years of screening. It failed to do so. Among cancers detected in people who received Galleri three years running, 60% were early stage — nearly identical to those receiving routine screening alone. There was a hint that Stage 4 incidence trended lower by the third year, but researchers say more time is needed to confirm whether that finding is real and whether it reduces mortality. There is currently no evidence the test lowers cancer death risk.
Wolf, writing in an analysis republished from The Conversation, was blunt: "Hope" does not reduce death and disability from cancer.
Safety data showed 0.6% of those tested underwent an invasive diagnostic procedure, with no serious complications — a record the 10-0 safety vote appears to reflect. But a positive result is a false alarm in about half of cases, prompting costly and sometimes risky follow-up testing.
What did the panelists say?
One panel member conceded the evidence gap. "So perhaps my 'yes' is a hopeful (vote) rather than an accurate one," the member said, arguing that finding more early-stage cancers in a broader population is a benefit even though that has not been proved.
Should patients get the test?
FDA approval would not guarantee insurance coverage. The Centers for Medicare and Medicaid Services runs a separate coverage determination process and is not required to cover FDA-approved tests. The out-of-pocket cost is currently US$949 per test — roughly $2,850 if taken annually over three years.
Wolf advises patients who pay out of pocket, accept a high false-alarm rate and resist false reassurance from negative results to consult their doctors. What is certain, he writes, is the importance of staying current with recommended screenings for colon, breast, cervical and lung cancers — the tests proven to detect early-stage disease and lower cancer death risk. That is the bottom line.
via fastcompany.com/rss (Source)
More from Elena Vasquez
Show full bio
Staff writer covering companies, deals and strategy in corporate strategy and chief-executive leadership at CEO Frontier.
489 articles
Adjacent sheets
- FDA Orders Eye-Stroke Warning on GLP-1 Drugs Used by 30 Million Americans
- Merck KGaA drops Silence heart drug after rival trial fails
- CDC: 44% of U.S. GLP-1 users changed how they take the drug
- FDA Orders Vision-Loss Warning on Ozempic, Wegovy, Zepbound Labels
- AstraZeneca weighs cancer vaccines as Phase 3 data emerge